Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 5/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.40 |
| ▸ | RORC | P51449 | 10/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980587 | 0.84 | GABRA2 (0.40) | GABRA2GABRB2RORCL3MBTL1 | |
| SCHEMBL2828429 | 0.82 | GABRA2 (0.45) | GABRA2GABRB2RORCCYP2C9CYP2C19 | |
| SCHEMBL2829556 | 0.79 | RORC (0.37) | GABRA2GABRB2RORCCYP2C9CYP3A4 | |
| SCHEMBL4411178 | 0.74 | GABRA2 (0.44) | GABRA2GABRB2RORCCYP2C9CYP2C19 | |
| SCHEMBL2829188 | 0.72 | MAPT (0.42) | GABRA2GABRB2RORCCYP2C9CYP3A4 | |
| SCHEMBL980011 | 0.71 | GABRA2 (0.38) | GABRA2GABRB2 | |
| SCHEMBL2831625 | 0.70 | MAPT (0.42) | GABRA2GABRB2CYP2C9CYP2C19 | |
| SCHEMBL2834112 | 0.69 | GABRA2 (0.43) | GABRA2GABRB2CYP2C9CYP2C19GAA | |
| SCHEMBL980293 | 0.68 | RORC (0.37) | GABRA2GABRB2RORCCYP2C9CYP3A4 | |
| SCHEMBL2830711 | 0.68 | HPGD (0.44) | GABRA2GABRB2RORCCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227538-A1 | N-(Hetero)Aryl Indole Derivatives as Pesticides | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227538-A1 | N-(Hetero)Aryl Indole Derivatives as Pesticides | IDO1, IDO2, CHRM1 | GABRA2 1275/4885GABRB2 1625/4885RORC 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.